Key Drivers
- Cash decline
- Negative equity
- Heavy cash burn
AIAI Summary
Nanobiotix has shifted from a pure R&D binary play to a momentum-and-financing dependent clinical developer where near-term valuation is driven by partnership narratives and milestone-based financing rather than fundamentals. The key actionable risk is acute liquidity and dilution exposure—monitor covenant timelines, milestone/royalty payment schedules, and quarterly cash burn closely, since missed payments or a negative trial headline would likely force dilutive financing and a sharp re-rating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash decline
- •Negative equity
- •Heavy cash burn
NBTX has meaningful cash and deferred revenue but faces worsening short-term liquidity, sustained large operating losses, negative equity, and stretched market valuation that together make it a high-risk, R&D-heavy speculative investment.
Price Behavior
Key Price Behavior Insights:
- •Higher March peak
- •Pulled below mean
- •Volatile swings
Price recovered from roughly $24.80 in late February to a March peak near $40 before pulling back below the last month mean (~$31.53) to about $29, signaling a bullish recovery now facing momentum loss and elevated volatility.
Rapid rise to $40.13 then a two-stage decline with large intraperiod swings
Sentiment & News
Key News Insights:
- •Management engagement
- •Equity disclosures
- •Price momentum
In late Feb–mid Mar 2026 Nanobiotix attracted intensified investor focus as management outreach and formal share-capital disclosures coincided with analyst attention and strong share-price moves (52‑week high and March 15 gap up).
Likely to support near-term liquidity and valuation upside, but investors should monitor potential capital-structure changes for dilution or governance impacts
Similar Companies in Healthcare
Other companies in the same sector with AI ratings